多发性骨髓瘤患者使用贝兰他单抗莫福汀后的角膜变化
Corneal Changes After Belantamab Mafodotin in Multiple Myeloma Patients.
作者信息
Bausell Rebecca B, Soleimani Arshia, Vinnett Alfred, Baroni Mariana D, Staub Sheila A, Binion Katrina, Jeng Bennie H, Badros Ashraf Z, Munir Wuqaas M
机构信息
Department of Ophthalmology and Visual Sciences (R.B.B., A.V., M.D.B., B.H.J., W.M.M.), University of Maryland School of Medicine, Baltimore, MD; The Marlene and Stewart Greenebaum Cancer Center (A.S., S.A.S., K.B., A.Z.B.), University of Maryland School of Medicine, Baltimore, MD.
出版信息
Eye Contact Lens. 2021 Jun 1;47(6):362-365. doi: 10.1097/ICL.0000000000000768.
OBJECTIVES
To describe progressive corneal microcyst-like epithelial changes (MECs) that developed in patients treated with the investigational drug belantamab mafodotin (belamaf) for refractory multiple myeloma (MM).
METHODS
This is a single center case series of patients with MM receiving the investigational drug belamaf.
RESULTS
All 12 patients included in this analysis who were treated with belamaf developed MECs that initially appeared in the peripheral cornea and progressed centrally with time. Cessation of therapy resulted in regression of the MECs first in the periphery then centrally. Microcyst-like epithelial changes recurred in all patients on retreatment. With prolonged therapy, eight patients developed corneal staining patterns suggestive of limbal stem cell dysfunction (LSCD).
CONCLUSION
We describe MECs and LSCD associated with systemic administration of belamaf. Further study is needed to determine the etiology and composition of the MECs and the mechanism of limbal stem cell involvement.
目的
描述在接受研究性药物贝兰他单抗马福多汀（belamaf）治疗难治性多发性骨髓瘤（MM）的患者中出现的进行性角膜微囊肿样上皮改变（MECs）。
方法
这是一个接受研究性药物belamaf治疗的MM患者的单中心病例系列。
结果
本分析中纳入的所有12例接受belamaf治疗的患者均出现MECs，最初出现在周边角膜，并随时间向中央进展。停止治疗导致MECs首先在周边然后在中央消退。所有患者再次治疗时微囊肿样上皮改变复发。随着治疗时间延长，8例患者出现提示角膜缘干细胞功能障碍（LSCD）的角膜染色模式。
结论
我们描述了与全身应用belamaf相关的MECs和LSCD。需要进一步研究以确定MECs的病因和组成以及角膜缘干细胞受累的机制。
Zotero 插件